Long-term, Follow-up Study of Subjects Who Completed Phase 3 Trials ATX-101-10-16 or ATX-101-10-17 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area
Latest Information Update: 05 Apr 2022
Price :
$35 *
At a glance
- Drugs Deoxycholic acid (Primary)
- Indications Subcutaneous fat disorders
- Focus Registrational; Therapeutic Use
- Sponsors Bayer; Kythera Biopharmaceuticals
- 27 Aug 2014 New source identified and integrated, European Clinical Trials Database record.
- 16 Feb 2014 New trial record